{"schema_version":"secwatch.filing_event.v1","accession":"0000879169-26-000006","form_type":"8-K","ticker":"INCY","cik":"0000879169","company_name":"INCYTE CORP","filed_at":"2026-02-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.888781+00:00","generated_at":"2026-05-16T03:45:58.694440+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Incyte Q4 total revenue $1.51B (+28% YoY); FY 2025 net product revenue beat guidance","bullets":["Q4 total revenue $1.51B (+28% YoY); net product revenue $1.22B (+20%). FY 2025 net product revenue $4.35B, above $4.23-4.32B guidance.","GAAP diluted EPS Q4 $1.46, FY $6.41; non-GAAP diluted EPS Q4 $1.80, FY $6.80.","2026 total net product revenue guidance $4.77-4.94B, including Jakafi $3.22-3.27B and Opzelura $750-790M.","Pipeline: positive frontMIND Phase 3 for tafasitamab in DLBCL; Jakafi XR filing submitted, decision mid-2026; INCA033989 registrational plans; ruxolitinib cream PN paused.","Cash $3.6B; entered option agreement with Prelude Therapeutics for JAK2V617F inhibitor program ($100M option exercise)."],"urls":{"canonical":"https://secwatch.observer/filing/0000879169-26-000006","json":"https://secwatch.observer/filing/0000879169-26-000006.json","markdown":"https://secwatch.observer/filing/0000879169-26-000006.md","text":"https://secwatch.observer/filing/0000879169-26-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879169/000087916926000006/0000879169-26-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879169/000087916926000006/incy-20260210.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T03:45:58.694440+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}